[Chinese Expert Consensus on Antiangiogenic Drugs for Advanced Non-small Cell Lung Cancer (2019 Edition)].
出版信息
Zhongguo Fei Ai Za Zhi. 2019 Jul 20;22(7):401-412. doi: 10.3779/j.issn.1009-3419.2019.07.01.
Abstract
摘要
相似文献
1
[Chinese Expert Consensus on Antiangiogenic Drugs for Advanced Non-small Cell Lung Cancer (2019 Edition)].《中国晚期非小细胞肺癌抗血管生成药物治疗专家共识（2019年版）》
Zhongguo Fei Ai Za Zhi. 2019 Jul 20;22(7):401-412. doi: 10.3779/j.issn.1009-3419.2019.07.01.
2
[Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)].《中国晚期非小细胞肺癌抗血管生成药物专家共识（2020年版）》
Zhonghua Zhong Liu Za Zhi. 2020 Dec 23;42(12):1063-1077. doi: 10.3760/cma.j.cn112152-20200918-00836.
3
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis
for Non-small Cell Lung Cancer (2020 Edition)].《中国非小细胞肺癌二代测序诊断专家共识（2020年版）》
Zhongguo Fei Ai Za Zhi. 2020 Sep 20;23(9):741-761. doi: 10.3779/j.issn.1009-3419.2020.101.45.
4
[Expert Consensus on Adjuvant Therapy of Non-small Cell Lung Cancer from China Thoracic Surgeons (2018 Version)].中国胸外科医师非小细胞肺癌辅助治疗专家共识（2018版）
Zhongguo Fei Ai Za Zhi. 2018 Oct 20;21(10):731-737. doi: 10.3779/j.issn.1009-3419.2018.10.01.
5
The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.老年肺癌患者抗血管生成药物的应用：专家小组讨论纪要
Clin Lung Cancer. 2017 May;18(3):255-258. doi: 10.1016/j.cllc.2016.12.001. Epub 2017 Jan 5.
6
Current and future strategies for antiangiogenic agents in non-small-cell lung cancer.非小细胞肺癌抗血管生成药物的当前及未来策略
Clin Lung Cancer. 2008 Mar;9 Suppl 2:S50. doi: 10.3816/CLC.2008.s.007.
7
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.贝伐单抗治疗非鳞状非小细胞肺癌：临床试验证据与经验
Ther Adv Respir Dis. 2016 Oct;10(5):485-91. doi: 10.1177/1753465816652083. Epub 2016 Jun 23.
8
Effects of microRNA regulation on antiangiogenic therapy resistance in non-small cell lung cancer.miRNA 调控对非小细胞肺癌抗血管生成治疗耐药的影响。
Biomed Pharmacother. 2020 Nov;131:110557. doi: 10.1016/j.biopha.2020.110557. Epub 2020 Aug 21.
9
[Angiogenesis and neoangiogenesis--the role in lung cancer and other tumors].[血管生成与新生血管生成——在肺癌及其他肿瘤中的作用]
Pneumonol Alergol Pol. 2006;74(4):414-20.
10
Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.抗血管生成药物与化疗治疗晚期非小细胞肺癌：临床观点。
Expert Rev Anticancer Ther. 2013 Oct;13(10):1193-206. doi: 10.1586/14737140.2013.845093.
引用本文的文献
1
Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway.黄芩素联合阿美替尼通过活性氧介导的PI3K/Akt途径对阿美替尼耐药的非小细胞肺癌细胞具有协同抗肿瘤活性。
Front Pharmacol. 2024 Jul 31;15:1405521. doi: 10.3389/fphar.2024.1405521. eCollection 2024.
2
LncRNA MRPL39 inhibits cell proliferation and migration by regulating miR-130/TSC1 axis in non-small cell lung cancer.长链非编码RNA MRPL39通过调控非小细胞肺癌中的miR-130/TSC1轴抑制细胞增殖和迁移。
3 Biotech. 2024 May;14(5):125. doi: 10.1007/s13205-024-03975-y. Epub 2024 Apr 2.
3
Insights into the pleiotropic roles of ZNF703 in cancer.对ZNF703在癌症中的多效性作用的见解。
Heliyon. 2023 Sep 14;9(9):e20140. doi: 10.1016/j.heliyon.2023.e20140. eCollection 2023 Sep.
4
Dysregulation of Pseudogenes/lncRNA-Hsa-miR-1-3p-PAICS Pathway Promotes the Development of NSCLC.假基因/长链非编码RNA-Hsa-miR-1-3p-PAICS通路失调促进非小细胞肺癌的发展。
J Oncol. 2022 Aug 30;2022:4714931. doi: 10.1155/2022/4714931. eCollection 2022.
5
Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) Patients.血浆 D-二聚体水平与非小细胞肺癌（NSCLC）患者的年龄、转移、复发、肿瘤-淋巴结-转移（TNM）分类和治疗相关。
Biomed Res Int. 2021 Oct 19;2021:9623571. doi: 10.1155/2021/9623571. eCollection 2021.
6
[Research Progress of Anti-angiogenic Agents Combined with Immunotherapy
in Patients with Advanced Non-small Cell Lung Cancer].抗血管生成药物联合免疫疗法治疗晚期非小细胞肺癌患者的研究进展
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):196-203. doi: 10.3779/j.issn.1009-3419.2021.101.05.
本文引用的文献
1
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
2
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.厄洛替尼联合贝伐珠单抗对比厄洛替尼单药治疗表皮生长因子受体阳性的晚期非鳞状非小细胞肺癌（NEJ026）：一项开放标签、随机、多中心、III 期临床试验的期中分析。
Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8.
3
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.阿替利珠单抗联合贝伐珠单抗和化疗治疗非小细胞肺癌（IMpower150）：一项随机、开放标签的 3 期临床试验中具有 EGFR 突变或基线肝转移患者的关键亚组分析。
Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.
4
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
5
Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.贝伐珠单抗联合化疗作为一线治疗方案用于中国晚期非小细胞肺癌患者的真实世界研究。
Thorac Cancer. 2018 Jul;9(7):805-813. doi: 10.1111/1759-7714.12650. Epub 2018 May 16.
6
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.纳武利尤单抗治疗经治晚期非小细胞肺癌的 5 年随访结果：CA209-003 研究结果。
J Clin Oncol. 2018 Jun 10;36(17):1675-1684. doi: 10.1200/JCO.2017.77.0412. Epub 2018 Mar 23.
7
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).安罗替尼三线治疗晚期难治性非小细胞肺癌的多中心、随机、II 期临床研究（ALTER0302）。
Br J Cancer. 2018 Mar 6;118(5):654-661. doi: 10.1038/bjc.2017.478. Epub 2018 Feb 13.
8
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.抗血管内皮生长因子的预测标志物和血管生成抑制剂作为免疫治疗药物的新作用。
Semin Cancer Biol. 2018 Oct;52(Pt 2):117-124. doi: 10.1016/j.semcancer.2017.12.002. Epub 2017 Dec 8.
9
Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?晚期非小细胞肺癌的联合免疫治疗策略：生物学原理是否符合临床需求？
Crit Rev Oncol Hematol. 2017 Nov;119:30-39. doi: 10.1016/j.critrevonc.2017.09.007. Epub 2017 Sep 19.
10
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.厄洛替尼联合贝伐珠单抗治疗晚期非小细胞肺癌的 II 期研究（JO25567）：更新的安全性结果。
Drug Saf. 2018 Feb;41(2):229-237. doi: 10.1007/s40264-017-0596-0.
Zotero 插件